Physicians are invited to attend CLL and MCL: Conventional Therapies and Transplant Options, a satellite symposium preceding the 2013 American Society of Hematology (ASH) Annual Meeting.
Using a case-based format and the latest research, experts will address the clinical management of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) and discuss both frontline and salvage therapies. Such therapies will include conventional chemotherapy, as well as transplant approaches. For CLL, what is the risk-adapted sequence for treatment and who can benefit from earlier and more aggressive therapeutic interventions, including hematopoietic cell transplantation (HCT)? For MCL, what are the optimal therapeutic approaches for this challenging disease using standard agents, novel approaches, and HCT?
- Thomas J. Kipps, M.D., Ph.D. Moores Cancer Center, University of California-San Diego, La Jolla, California
- Peter Dreger, M.D. University of Heidelberg, Heidelberg, Germany
- Ajay Gopal, M.D. University of Washington, Seattle, Washington
- Julie Vose, M.D., MBA University of Nebraska Medical Center, Omaha, Nebraska
- Ginna Laport, M.D. (moderator) Stanford University, Stanford, California